Pandora's Basket? Overenthusiasm May Be Side Effect Of Biomarker-Driven Trials
Executive Summary
Sponsors stress that basket trials are designed to find signals of activity that will be followed up with randomized, controlled studies, but NEJM editorial wonders if off-label prescribing will circumvent those intentions.
You may also be interested in...
Cancer Progress Requires Integrating Data And Therapeutics – AACR Report
As genomic analysis produces ever-increasing amounts of data on cancer biology, continued progress in oncology will require advances in managing and analyzing data and new approaches to clinical trial design to increase efficiency and address development of treatment resistance to molecularly targeted therapies, the American Association for Cancer Research asserts in its annual Cancer Progress report.
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.
BeiGene’s Tevimbra And The End Of The COVID Inspection Era
US FDA approves the PD-1 inhibitor 20 months after user fee goal, resolving one of the last applications delayed by China’s extended pandemic travel restrictions.